
    
      This is a Phase 1 study to evaluate the safety, tolerability and PK of MGD010, a CD32B x
      CD79B DART bi-specific antibody-based molecule. This study will be conducted as a
      double-blind, randomized, placebo controlled, single ascending dose study among healthy
      subjects.
    
  